Current treatment guidelines recommend using cancer antigen-125 (CA-125) as a diagnostic marker for ovarian cancer recurrence, but a recent study suggests CA-125 has poor concordance with progressive ...

Cancer Antigen 125 (CA-125) testing shows 23% lower odds of elevated levels in American Indian and Black patients with ovarian cancer compared with White patients. Patients with false-negative CA-125 ...

Please provide your email address to receive an email when new articles are posted on . CA-125 is a “useful test” for ovarian cancer in primary care, especially in symptomatic women aged older than 50 ...

The accuracy of the cancer antigen (CA)–125 test in predicting ovarian cancer varies by ethnicity, primarily due to factors like age and comorbidities rather than ethnicity itself. General ...

The likelihood of having an elevated CA-125 level at ovarian cancer diagnosis was lower for American Indian, Asian, or Black patients versus White patients. HealthDay News — Black and American Indian ...

Oncologists use measurement of response as an indicator that the therapy they are administering is effective. This information can then be used to decide whether to continue, change, or stop therapy ...

Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated Levels. If you have the appropriate software installed, you can download article citation data to the ...

DEAR DR. ROACH: I have a history of cancer with an elevated CA-125 level. Recently I had a shingles shot and soon thereafter, my CA-125 level was high. An extensive workup showed up nothing ...

Should I ask my doctor for a CA 125 blood test to screen for ovarian cancer? The cancer antigen 125 (CA 125) blood test isn't recommended for women with an average risk of ovarian cancer. While women ...

HOUSTON - Evaluating its change over time, CA-125, the protein long-recognized for predicting ovarian cancer recurrence, now shows promise as a screening tool for early-stage disease, according to ...

“[...] these inexpensive, widely available tests with rapid turnaround times and relatively short half-lives (CEA, CA-125, and CA19-9) are perfectly situated to ...

Serum CA-125 is a promising diagnostic biomarker for ovarian cancer, but screening studies using fixed CA-125 cutoffs have not shown a mortality benefit in the general (low-risk) population. New data ...